Cited by 219Psychedelics and Drug StudiesNeurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatment

The DOI matches its Crossref record; 86 of the 87 references it cites were found in a registry or an index.

Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG

Gouzoulis-Mayfrank, E·1999·Neuropsychopharmacology

DOI 10.1016/s0893-133x(98)00089-x

Open this paper in CoChat — free account

Abstract

The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4-methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2-0.4 mg/kg) and the drugs' interactions with a prefrontal activation task were investigated in a double-blind, placebo-controlled human [F-18]fluorodeoxyglucoseFDG-positron emission tomographicPET study (each group: n = 8). Subjects underwent two scans (control: word repetition; activation word association) within 2-4 weeks. Psilocybin increased rMRGlu in distinct right hemispheric frontotemporal cortical regions, particularly in the anterior cingulate and decreased rMRGlu in the thalamus. Both MDE and METH induced cortical hypometabolism and cerebellar hypermetabolism. In the MDE group, cortical hypometabolism was more pronounced in frontal regions, with the exception of the right anterior cingulate, which tended to be hyperactive. Cognitive activation-related increases in left frontocortical regions were attenuated under all three psychoactive substances, but less so under MDE. Taking into account performance data and subjective reports on task difficulty, these effects may result from different mechanisms across the three groups. Our PSI data are in line with studies on acute schizophrenic patients suggesting frontal overactivity at rest, but diminished capacity to activate prefrontal regions upon cognitive demand. The MDE data support the hypothesis that entactogens constitute a distinct psychoactive substance class, which takes an intermediate position between stimulants and hallucinogens.

Integrity signals

Registry

Crossref · 10.1016/s0893-133x(98)00089-x

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
THE [ 14 C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1
Sokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000
Dementia Praecox or the Group of Schizophrenias
(1951) · Journal of the American Medical Association · doi:10.1001/jama.1951.02920270079043 · Cited by 4,407
Contributions of anterior cingulate cortex to behaviour
Devinsky, O., Morrell, M. J., & Vogt, B. A. (1995) · Brain · doi:10.1093/brain/118.1.279 · Cited by 3,377
Positron emission tomographic studies of the cortical anatomy of single-word processing
Petersen, S. E., Fox, P. T., Posner, M. I., Mintun, M., & Raichle, M. E. (1988) · Nature · doi:10.1038/331585a0 · Cited by 2,593
Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method
Phelps, M. E., Huang, S. C., Hoffman, E. J., Selin, C. E., Sokoloff, L., & Kuhl, D. E. (1979) · Annals of Neurology · doi:10.1002/ana.410060502 · Cited by 2,417
Dementia Praecox oder Gruppe der Schizophrenien
Bleuler, E. (1911) · Cited by 1,429
Functional Heterogeneity in Cingulate Cortex: The Anterior Executive and Posterior Evaluative Regions
Vogt, B. A., Finch, D. M., & Olson, C. R. (1992) · Cerebral Cortex · doi:10.1093/cercor/2.6.435-a · Cited by 1,315
Patterns of Cerebral Blood Flow in Schizophrenia
Liddle, P. F., Friston, K. J., Frith, C., Hirsch, S. R., Jones, T., & Frackowiak, R. S. J. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.160.2.179 · Cited by 899

Show all 87 references

Sorted by citations

Psychedelics
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Hallucinogens
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects
Gasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
Methamphetamine use behaviors and gender differences
Brecht, M., O’Brien, A., von Mayrhauser, C., & Anglin, M. D. (2003) · Addictive Behaviors · doi:10.1016/s0306-4603(03)00082-0 · Cited by 444
Serotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons
Rippeth, J. D., Heaton, R. K., Carey, C. L., Marcotte, T. D., Moore, D. J., González, R., Wolfson, T. J., Grant, I., & the HNRC Group (2004) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617704101021 · Cited by 435
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01706-y · Cited by 356
Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
A systems model of altered consciousness: integrating natural and drug-induced psychoses
Vollenweider, F. X., & Geyer, M. A. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00646-3 · Cited by 339
Cognitive consequences of cannabis use: Comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions
Lundqvist, T. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.02.017 · Cited by 331
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
“…et al., 1994) Double-blind studies have confirmed the APZ and the HRS can distinguish the effects of psilocybin and mescaline from those of (+)-methamphetamine, methylphenidate, and 3,4-methylenedioxyethylamphetamine (Hermle et al., 1992; Gouzoulis-Mayfrank et al., 1999b; Griffiths et al., 2006).”
BackgroundInfluential
Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers
Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119845793 · Cited by 225
Phenomenology, Structure, and Dynamic of Psychedelic States
Preller, K. H., & Vollenweider, F. X. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_459 · Cited by 282
Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates
Barrett, F. S., & Griffiths, R. R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_474 · Cited by 273
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 308
Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin
Mason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0718-8 · Cited by 258
Higher Cortical and Lower Subcortical Metabolism in Detoxified Methamphetamine Abusers
Volkow, N. D., Chang, L., Wang, G., Fowler, J. S., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y., Wong, C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.383 · Cited by 249
The Therapeutic Potential of Psilocybin
Lowe, H. I. C., Toyang, N. J., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W. F., & Gordon, L. (2021) · Molecules · doi:10.3390/molecules26102948 · Cited by 282
Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
Riba, J., Romero, S., Grasa, E., Mena, E., Carrió, I., & Barbanoj, M. J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0358-7 · Cited by 241
Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers
Quednow, B. B., Kometer, M., Geyer, M. A., & Vollenweider, F. X. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.228 · Cited by 240
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews
SANTOS, R. G. D., Bouso, J. C., Alcázar‐Córcoles, M. Á., & Hallak, J. E. C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1511424 · Cited by 244
Ayahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
Effect of Psilocybin on Empathy and Moral Decision-Making
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx047 · Cited by 197
Differential Postnatal Development of Catecholamine and Serotonin Inputs to Identified Neurons in Prefrontal Cortex of Rhesus Monkey
Lambe, E. K., Krimer, L. S., & Goldman-Rakic, P. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08780.2000 · Cited by 204
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4377-8 · Cited by 201
Models of psychedelic drug action: modulation of cortical-subcortical circuits
Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M. B., Griffiths, R. R., Mathur, B. N., & Barrett, F. S. (2021) · Brain · doi:10.1093/brain/awab406 · Cited by 217
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Garcia‐Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 210
The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans
Schreckenberger, M., Lange‐Asschenfeldt, C., Lochmann, M., Mann, K., Siessmeier, T., Buchholz, H., Bartenstein, P., & Gründer, G. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.01.047 · Cited by 187
Psilocybin: from ancient magic to modern medicine
Nichols, D. E. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0311-8 · Cited by 221
Understanding Drug Addiction: A Neuropsychological Perspective
Yücel, M., Lubman, D. I., Solowij, N., & Brewer, W. J. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701689444 · Cited by 198
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
3,4-Methylenedioxymethamphetamine (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by [H215O]-PET in Healthy Humans
Gamma, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00130-5 · Cited by 162
Methamphetamine Activates Reward Circuitry in Drug Naïve Human Subjects
Vӧllm, B., de Araújo, I. E., Cowen, P. J., Rolls, E. T., Kringelbach, M. L., Smith, K., Jezzard, P., Heal, R. J., & Matthews, P. M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300481 · Cited by 160
Dimensions of consciousness and the psychedelic state
Bayne, T., & Carter, O. (2018) · Neuroscience of Consciousness · doi:10.1093/nc/niy008 · Cited by 142
Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations
Kometer, M., Pokorny, T., Seifritz, E., & Volleinweider, F. X. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4026-7 · Cited by 169
Abnormal reward functioning across substance use disorders and major depressive disorder: Considering reward as a transdiagnostic mechanism
Baskin-sommers, A. R., & Foti, D. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2015.01.011 · Cited by 173
Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations
Müller, F., Lenz, C., Dolder, P. C., Lang, U. E., Schmidt, A., Liechti, M. E., & Borgwardt, S. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12818 · Cited by 144
The History of Psychedelics in Psychiatry
Nichols, D. E., & Walter, H. (2020) · Pharmacopsychiatry · doi:10.1055/a-1310-3990 · Cited by 134
Effects of the South American Psychoactive Beverage Ayahuasca on Regional Brain Electrical Activity in Humans: A Functional Neuroimaging Study Using Low-Resolution Electromagnetic Tomography
Riba, J., Anderer, P., Jané, F., Saletu, B., & Barbanoj, M. J. (2004) · Neuropsychobiology · doi:10.1159/000077946 · Cited by 134
Brain mechanisms of hallucinogens and entactogens
Vollenweider, F. X. (2001) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2001.3.4/fxvollenweider · Cited by 129
Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure
González, R., Rippeth, J. D., Carey, C. L., Heaton, R. K., Moore, D. J., Schweinsburg, B. C., Cherner, M., & Grant, I. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.04.014 · Cited by 128
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G. L., Giaroli, G., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 127
The early use of MDMA (‘Ecstasy') in Psychotherapy (1977–1985)
Passie, T. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518767442 · Cited by 116
Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses
McCulloch, D. E.-W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104689 · Cited by 110
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow
Lewis, C. R., Preller, K. H., Kraehenmann, R., Michels, L., Staempfli, P., & Vollenweider, F. X. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.020 · Cited by 102
Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man
Hasler, F., Bourquin, D., Brenneisen, R., & Vollenweider, F. X. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00278-9 · Cited by 100
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3167-9 · Cited by 96
Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study
NORDAHL, T. E., Salo, R. E., Possin, K. L., Gibson, D. R., Flynn, N. M., Leamon, M. H., Galloway, G. P., Pfefferbaum, A., Spielman, D. M., Elfar Adalsteinsson, A., et al. (2002) · Psychiatry Research Neuroimaging · doi:10.1016/s0925-4927(02)00088-4 · Cited by 95
Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder
Murnane, K. S. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000459 · Cited by 90
No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study
Gamma, A., Buck, A., Berthold, T., & Vollenweider, F. X. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00012 · Cited by 84
A review on research and evaluation methods for investigating self-transcendence
Kitson, A., Chirico, A., Gaggioli, A., & Riecke, B. E. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.547687 · Cited by 76
Hallucinogen-Induced UP States in the Brain Slice of Rat Prefrontal Cortex: Role of Glutamate Spillover and NR2B-NMDA Receptors
Lambe, E. K., & Aghajanian, G. K. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300944 · Cited by 75
Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol
Stebelska, K. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31828741a5 · Cited by 76
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users
Frankel, P. S., Alburges, M. E., Bush, L. G., Hanson, G. R., & Kish, S. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.019 · Cited by 72
Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics
Luethi, D., & Liechti, M. E. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy047 · Cited by 70
Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse
Berman, S. M., Voytek, B., Mandelkern, M. A., Hassid, B. D., Isaacson, A. J., Monterosso, J. R., Miotto, K. A., Ling, W. W., & London, E. D. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002107 · Cited by 74
Effects of the Hallucinogen Psilocybin on Covert Orienting of Visual Attention in Humans
Gouzoulis‐Mayfrank, E., Thelen, B., Maier, S., Heekeren, K., Kovar, K. ‐., Sass, H., & Spitzer, M. (2002) · Neuropsychobiology · doi:10.1159/000063672 · Cited by 69
Self-citation
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca
McKenna, D. J., & Jordi Riba, A. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_472 · Cited by 69
Imaging Cognitive Deficits in Drug Abuse
Lundqvist, T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_26 · Cited by 64
Acute Alcohol Effects on Neuronal and Attentional Processing: Striatal Reward System and Inhibitory Sensory Interactions under Acute Ethanol Challenge
Schreckenberger, M., Amberg, R., Scheurich, A., Lochmann, M., Tichy, W., Klega, A., Siessmeier, T., Gründer, G., Buchholz, H., Landvogt, C., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300453 · Cited by 63
Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis
Daumann, J., Wagner, D. R., Heekeren, K., Neukirch, A., Thiel, C. M., & Gouzoulis‐Mayfrank, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109103227 · Cited by 62
Self-citation
Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities
Yaden, D. B., Johnson, M. W., Griffiths, R. R., Doss, M. K., Garcia‐Romeu, A., Nayak, S. M., Gukasyan, N., Mathur, B. N., & Barrett, F. S. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab026 · Cited by 69
Genuine and drug-induced synesthesia: A comparison
Sinke, C., Halpern, J. H., Zedler, M., Neufeld, J., Emrich, H. M., & Passie, T. (2012) · Consciousness and Cognition · doi:10.1016/j.concog.2012.03.009 · Cited by 62
Positron Emission Tomography Study of Regional Cerebral Metabolism during General Anesthesia with Xenon in Humans
Rex, S., Schaefer, W. M., Meyer, P. H., Rossaint, R., Boy, C., Setani, K., Büll, U., & Baumert, J. ‐. (2006) · Anesthesiology · doi:10.1097/00000542-200611000-00014 · Cited by 58
Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans
Spitzer, M., Franke, B., Walter, H., Buechler, J., Wunderlich, A. P., Schwab, M. G., Kovar, K., Hermle, L., & Grön, G. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00060-0 · Cited by 57
Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis
Daumann, J., Heekeren, K., Neukirch, A., Thiel, C. M., Möller‐Hartmann, W., & Gouzoulis‐Mayfrank, E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1237-1 · Cited by 53
Self-citation
The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability
Carhart-Harris, R. L., Williams, T. A., Sessa, B., Tyacke, R. J., Rich, A. S., Feilding, A., & Nutt, D. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110367445 · Cited by 52
Lysergic acid diethylamide: a drug of ‘use’?
Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316640440 · Cited by 53
Inhibition of Return in the Human 5HT2A Agonist and NMDA Antagonist Model of Psychosis
Gouzoulis‐Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Daumann, J., Obradovic, M., & Kovar, K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300882 · Cited by 48
Self-citation
UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice
Rijsketic, D. R., Casey, A. B., Barbosa, D. A. N., Zhang, X., Hietamies, T. M., Ramirez-Ovalle, G., Pomrenze, M. B., Halpern, C. H., Williams, L. M., Malenka, R. C., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01613-4 · Cited by 46
Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing—study on P300 and mismatch negativity in healthy volunteers
Bravermanová, A., Viktorinová, M., Tylš, F., Novák, T., Androvičová, R., Korčák, J., Horáček, J., Balíková, M., Griškova-Bulanova, I., Danielová, D., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4807-2 · Cited by 50
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler, E. A. D., Wallace, R. M., Sloshower, J., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 51
Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States
Avram, M., Rogg, H. V., Korda, A. I., Andreou, C., Müller, F., & Borgwardt, S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.706017 · Cited by 49
Serotonin–Glutamate Interactions A New Target for Antipsychotic Drugs
Aghajanian, G. K. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00106-2 · Cited by 44
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43
Neuroimaging in psychedelic drug development: past, present, and future
Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 43
The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA)
Freudenmann, R. W., & Spitzer, M. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00007.x · Cited by 42
Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids
Andersson, C., Gry, J., & Kristinsson, J. (2009) · TemaNord · doi:10.6027/tn2008-606 · Cited by 41
Metabolic Syndrome in Drug Abuse
Virmani, A., BINIENDA, Z. K., Ali, S. F., & Gaetani, F. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1403.004 · Cited by 42
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Gründer, G., & Jungaberle, H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1486-7386 · Cited by 39
Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors
Strumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 40
Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain
Spain, A., Howarth, C., Khrapitchev, A. A., Sharp, T., Sibson, N. R., & Martin, C. J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.018 · Cited by 37
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research
Wen, A. Q., Singhal, N., Jones, B. D. M., Zeifman, R. J., Mehta, S. H., Shenasa, M. A., Blumberger, D. M., Daskalakis, Z. J., & Weissman, C. R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0028 · Cited by 42
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 35
Altered energy production, lowered antioxidant potential, and inflammatory processes mediate CNS damage associated with abuse of the psychostimulants MDMA and methamphetamine
Downey, L. A., & Loftis, J. M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.032 · Cited by 36
Psilocybin’s effects on cognition and creativity: A scoping review
Bonnieux, J. N., VanderZwaag, B., Premji, Z., Garcia‐Romeu, A., & García-Barrera, M. A. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179801 · Cited by 38
High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin
Braun, D., Rosenberg, A. M., Rabaniam, E., Haruvi, R., Malamud, D., Barbara, R., Aiznkot, T., Levavi‐Sivan, B., & Kawashima, T. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02391-7 · Cited by 42
The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies
Castelhano, J., Lima, G., Teixeira, M., Soares, C., Pais, M. L., & Castelo-Branco, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739053 · Cited by 41

Authors: Gouzoulis-Mayfrank, E.
Venue: Neuropsychopharmacology
Publisher: Springer Science and Business Media LLC
Published: 1999-06
Volume: 20
Issue: 6
Pages: 565-581
ISSN: 0893-133X (ISSN-L)
DOI: 10.1016/s0893-133x(98)00089-x
OpenAlex: W2102963347
Cited by: 219
References: 87
Citations by year: 2026: 10 · 2025: 12 · 2024: 10 · 2023: 32 · 2022: 11 · 2021: 16 · 2020: 9 · 2019: 2 · 2018: 11 · 2017: 7 · 2016: 13 · 2015: 5 · 2014: 8 · 2013: 3 · 2012: 5
FWCI: 7.68
Type: journal article
Language: en
Open access: closed
Locations: Neuropsychopharmacology (publishedVersion)
PubMed (publishedVersion)
RWTH Publications (RWTH Aachen) (submittedVersion)
Funders: Deutsche Forschungsgemeinschaft
Eberhard Karls Universität Tübingen
RWTH Aachen University
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords: psilocybin, MDMA, hallucinogens, entactogens, stimulants, brain glucose metabolism, 18F-FDG PET, prefrontal cortex, anterior cingulate cortex, thalamus, cerebellar hypermetabolism, cognitive activation, word association task, healthy volunteers
MeSH terms: Adult, Cerebellum, Cognition, Double-Blind Method, Female, Glucose, Hallucinogens, Humans, Magnetic Resonance Imaging, Male, Methamphetamine, Middle Aged, Psilocybin, Psychopathology, Radionuclide Imaging, 3,4-Methylenedioxyamphetamine, Adrenergic Agents, Nootropic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks